Clinical analysis of liposomal doxorubicin-based regimens for treatment of adult patients with T-cell lymphoma
10.3760/cma.j.cn115355-20190822-00376
- VernacularTitle:含脂质体多柔比星方案治疗成年人T细胞淋巴瘤临床分析
- Author:
Kaili ZHONG
1
;
Bin WANG
;
Weixia WANG
;
Lefu HUANG
;
Weijing ZHANG
Author Information
1. 首都医科大学附属北京世纪坛医院淋巴肿瘤科 100038
- From:
Cancer Research and Clinic
2020;32(5):352-356
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effects and adverse reactions of the liposomal doxorubicin-based regimens in the treatment of adult patients with T-cell lymphoma.Methods:The clinical data of patients with T-cell lymphoma who were diagnosed and treated in Beijing Shijitan Hospital of Capital Medical University from August 2012 to May 2016 was retrospectively analyzed. All patients received chemotherapy containing liposomal doxorubicin. The clinical manifestations, treatment results, and adverse reactions were observed.Results:A total of 16 patients were enrolled, with a median age of 50.5 years old (16-81 years old), of which 7 patients were newly treated and 9 patients were retreated (including 5 refractory patients). Eleven of the 16 patients were evaluated for efficacy, including 4 cases of complete remission (CR) and 4 cases of partial remission (PR), the overall response rate was 72.8% (8/11). With a median follow-up of 11 months, the 2-year progression-free survival rate and overall survival rate were 42.4% and 41.6%. All 5 primary skin T-cell lymphoma patients were refractory or relapsed with 1 case of CR and 4 cases of PR after treatment. The adverse reactions were acceptable.Conclusions:The remission rate of liposomal doxorubicin-based regimens for treatment of adult patients with T-cell lymphoma is promising, especially for newly-treated patients. Primary skin T-cell lymphoma patients might be more likely to benefit from liposomal doxorubicin-based regimens.
